SinoMab BioScience (FRA:4VF) 3-Year Share Buyback Ratio: -10.20% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4VF SinoMab BioScience Ltd FRA:4VF
19 GF Score
Price €0.12
! 2 Warning Signs
View Full Analysis

What is SinoMab BioScience 3-Year Share Buyback Ratio?

SinoMab BioScience FRA:4VF 19 3-Year Share Buyback Ratio is -10.20 as of Dec. 2025. GuruFocus rates FRA:4VF with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,188 Biotechnology companies, SinoMab BioScience ranks better than 52.78% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. SinoMab BioScience's current 3-Year Share Buyback Ratio was -10.20%.

The historical rank and industry rank for SinoMab BioScience's 3-Year Share Buyback Ratio or its related term are showing as below:

FRA:4VF' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -10.2   Med: -0.9   Max: 0
Current: -10.2

During the past 9 years, SinoMab BioScience's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -10.20%. And the median was -0.90%.

FRA:4VF's 3-Year Share Buyback Ratio is ranked better than
52.78% of 1188 companies
in the Biotechnology industry
Industry Median: -11.75 vs FRA:4VF: -10.20

SinoMab BioScience (FRA:4VF) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


SinoMab BioScience 3-Year Share Buyback Ratio Related Terms


FRA:4VF vs VRTX, REGN, MRNA: 3-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, SinoMab BioScience's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SinoMab BioScience 3-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's 3-Year Share Buyback Ratio falls into.


FRA:4VF
19GF Score
SinoMab BioScience Ltd FRA:4VF
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SinoMab BioScience 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -10.20 mean?
SinoMab BioScience (FRA:4VF) has a 3-Year Share Buyback Ratio of -10.20 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for SinoMab BioScience and its competitors. According to the industry distribution chart, SinoMab BioScience ranks #561 out of 1188 companies in the Biotechnology industry, placing it in the top 47.2%.
Is SinoMab BioScience's 3-Year Share Buyback Ratio too high?
SinoMab BioScience's current 3-Year Share Buyback Ratio is -10.20. Based on the distribution chart, SinoMab BioScience ranks #561 out of 1188 companies in the Biotechnology industry, which is above the industry midpoint. Overall, SinoMab BioScience has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does SinoMab BioScience's 3-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SinoMab BioScience ranks #561 out of 1188 companies for 3-Year Share Buyback Ratio. This puts SinoMab BioScience in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for SinoMab BioScience and its competitors. SinoMab BioScience's current 3-Year Share Buyback Ratio is -10.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SinoMab BioScience stock overvalued right now?
SinoMab BioScience (FRA:4VF) has a current 3-Year Share Buyback Ratio of -10.20. The current 3-Year Share Buyback Ratio is -10.20. SinoMab BioScience's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For SinoMab BioScience (FRA:4VF), the current 3-Year Share Buyback Ratio is -10.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SinoMab BioScience Business Description

Other Exchanges 03681:Hong Kong
Address No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company focused on the research, development, manufacturing, and commercialisation of therapeutics for the treatment of immunological diseases, mainly monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. In addition, the company possesses other potential first-in-class drug candidates (like SM17, SN1011, SM06, SM09, etc.) some of which are already in the clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases.
19GF Score

Get the complete analysis for FRA:4VF

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price